In addition to supporting resubmission of the new drug application (NDA) for Shire PLC's dry-eye disease candidate lifitegrast, the specialty pharma is emphasizing that the just-completed OPUS-3 trial shows that lifitegrast is the first drug ever to demonstrate symptom improvement over consecutive trials in dry eye.
In addition to supporting resubmission of the new drug application (NDA) for Shire PLC's dry-eye disease candidate lifitegrast, the specialty pharma is emphasizing that the just-completed OPUS-3 trial shows that lifitegrast is the first drug ever to demonstrate symptom improvement over consecutive trials in dry eye.
When Shire revealed that it received a complete response letter (CRL) on Oct. 16, it signaled to investors that it...
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
